SCHEMBL3277964

SCHEMBL3277964

CC(C)(NC(=O)OCc1ccccc1)C(=N)N

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 1/20 0.47
CTSS P25774 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.46
PLAU P00749 2/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3277959 0.99 MEN1 (0.51) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL2268248 0.88 MEN1 (0.55) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL503402 0.88 MEN1 (0.57) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL12590895 0.85 MEN1 (0.52) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL10349980 0.84 ALDH1A1 (0.58) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL6444094 0.83 MEN1 (0.56) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL1150661 0.83 MEN1 (0.50) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL1150660 0.83 MEN1 (0.50) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL8267137 0.83 MEN1 (0.50) MEN1KMT2ASMN1; SMN2CA12CA1
SCHEMBL31326042 0.82 MEN1 (0.52) MEN1KMT2ASMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586444-B1 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition MERCK SHARP & DOHME (US) 2019-09-25 EP disclosed
EP-3165220-B1 PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-NUCLEATING AGENT MERCK SHARP & DOHME (US) 2019-04-03 EP disclosed
US-8592436-B2 Arylamide pyrimidone derivatives SANOFI (FR) 2013-11-26 US disclosed
EP-2148866-B1 ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI SA (FR) 2013-07-17 EP disclosed
US-20100087460-A1 ARYLAMIDE PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2010-04-08 US disclosed
EP-1992620-A1 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases Sanofi-Aventis (FR) 2008-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087460-A1 ARYLAMIDE PYRIMIDONE DERIVATIVES DHFR, XDH, HPRT1 MEN1 1547/4885KMT2A 2609/4885SMN1; SMN2 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.